The World Health Organization (WHO) has approved the COVID-19 vaccine CONVIDECIA, developed by the Chinese company CanSino Biologics Inc., for emergency use. Xinhua reports.
According to the news agency, this is the third Chinese vaccine included in the list of drugs recommended for emergency use. Sinopharm and Sinopec vaccines have been previously approved.
The WHO statement notes that the evaluation of the CONVIDECIA vaccine «is based on an analysis of data on quality, safety, efficacy, risk management plan and program compatibility, as well as the results of a WHO inspection of the place of production of the vaccine.»
The one-component CONVIDECIA vaccine is «based on a modified human adenovirus». The effectiveness of the vaccine was 64 percent against the symptomatic course of the disease and 92 percent against the severe course.
